Skip to main content

Market Overview

Hologic Investors Cheer As Barclays Upgrades To Overweight: 'Stronger For Longer' On Breast Health

Share:
Hologic Investors Cheer As Barclays Upgrades To Overweight: 'Stronger For Longer' On Breast Health

Shares of Hologic, Inc. (NASDAQ: HOLX) rose about 1 percent in the Friday pre-market hours after Barclays upgraded the shares to Overweight from Equal Weight, saying the company can grow "stronger for longer" versus its previous expectations.

The brokerage, who also upped the price target by $2 to $44, believes the breast health business will be able to sustain its L-MSD growth with a longer 3D mammography tail, service growth from 3D conversions, and new product launches such as Affirm.

"Our FDA mammography market model improves our conviction in the durability of placements and Hologic share gains," analyst Jack Meehan wrote in a note.

In addition, the Meehan said the company's Panther system strengthened its leadership position at the high-end of MDx workflows and can drive L-MSD growth for the entire diagnostics business alone.

Related Link: New 5-Year Contraceptive Coming To U.S. Adds To Long-Acting, Reversible Contraceptives List

"The launch of the Fusion PCR sidecar in 2017/2018 will add additional flexibility to the instrument, which could lead to higher consumable pull-through, as the company expands its US menu beyond sexual health into virology," Meehan highlighted.

Importantly, the analyst feels that Panther is "PAMA-proof" for upcoming Dx reimbursement changes, and could be an aggregator of share in a consolidating lab market. Further, the analyst expects at least HSD growth for the GYN Surgical unit from MyoSure strength.

"We believe that at current levels shares offer an attractive entry point, flat YTD versus the S&P 500 up 6 percent and our coverage universe up 15 percent," Meehan added.

Shares of Hologic closed Thursday's regular trading at $38.78. The revised target of $44 represents a potential upside of 13 percent.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for HOLX

DateFirmActionFromTo
Apr 2021JefferiesMaintainsBuy
Feb 2021BairdMaintainsBuy
Dec 2020Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for HOLX
View the Latest Analyst Ratings

 

Related Articles (HOLX)

View Comments and Join the Discussion!

Posted-In: Analyst Color Long Ideas News Upgrades Health Care Price Target Analyst Ratings Movers Best of Benzinga

Latest Ratings

StockFirmActionPT
ALHCUBSInitiates Coverage On28.0
EWTXWedbushInitiates Coverage On38.0
CITKeefe, Bruyette & WoodsUpgrades62.0
FISRosenblattMaintains146.0
TDUPWilliam BlairInitiates Coverage On
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com